These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24098755)

  • 1. Regorafenib effects on human colon carcinoma xenografts monitored by dynamic contrast-enhanced computed tomography with immunohistochemical validation.
    Cyran CC; Kazmierczak PM; Hirner H; Moser M; Ingrisch M; Havla L; Michels A; Eschbach R; Schwarz B; Reiser MF; Bruns CJ; Nikolaou K
    PLoS One; 2013; 8(9):e76009. PubMed ID: 24098755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
    Cyran CC; von Einem JC; Paprottka PM; Schwarz B; Ingrisch M; Dietrich O; Hinkel R; Bruns CJ; Clevert DA; Eschbach R; Reiser MF; Wintersperger BJ; Nikolaou K
    Invest Radiol; 2012 Jan; 47(1):49-57. PubMed ID: 21934514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of perfusion MRI and 18F-FDG PET imaging biomarkers for monitoring regorafenib therapy in experimental colon carcinomas with immunohistochemical validation.
    Eschbach RS; Fendler WP; Kazmierczak PM; Hacker M; Rominger A; Carlsen J; Hirner-Eppeneder H; Schuster J; Moser M; Havla L; Schneider MJ; Ingrisch M; Spaeth L; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(2):e0115543. PubMed ID: 25668193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation.
    Eschbach RS; Clevert DA; Hirner-Eppeneder H; Ingrisch M; Moser M; Schuster J; Tadros D; Schneider M; Kazmierczak PM; Reiser M; Cyran CC
    PLoS One; 2017; 12(1):e0169323. PubMed ID: 28060884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.
    Kazmierczak PM; Burian E; Eschbach R; Hirner-Eppeneder H; Moser M; Havla L; Eisenblätter M; Reiser MF; Nikolaou K; Cyran CC
    PLoS One; 2015; 10(9):e0138452. PubMed ID: 26393949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
    Cyran CC; Paprottka PM; Schwarz B; Sourbron S; Ingrisch M; von Einem J; Pietsch H; Dietrich O; Hinkel R; Bruns CJ; Reiser MF; Wintersperger BJ; Nikolaou K
    AJR Am J Roentgenol; 2012 Feb; 198(2):384-91. PubMed ID: 22268182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monitoring early response to anti-angiogenic therapy: diffusion-weighted magnetic resonance imaging and volume measurements in colon carcinoma xenografts.
    Schneider MJ; Cyran CC; Nikolaou K; Hirner H; Reiser MF; Dietrich O
    PLoS One; 2014; 9(9):e106970. PubMed ID: 25222284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
    Cyran CC; Schwarz B; Paprottka PM; Sourbron S; von Einem JC; Dietrich O; Hinkel R; Clevert DA; Bruns CJ; Reiser MF; Nikolaou K; Wintersperger BJ
    Cancer Imaging; 2013 Dec; 13(4):557-66. PubMed ID: 24380871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-energy computed tomography for the assessment of early treatment effects of regorafenib in a preclinical tumor model: comparison with dynamic contrast-enhanced CT and conventional contrast-enhanced single-energy CT.
    Knobloch G; Jost G; Huppertz A; Hamm B; Pietsch H
    Eur Radiol; 2014 Aug; 24(8):1896-905. PubMed ID: 24871332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic contrast-enhanced computed tomography to assess antitumor treatment effects: comparison of two contrast agents with different pharmacokinetics.
    Jost G; Pietsch H; Grenacher L
    Invest Radiol; 2013 Oct; 48(10):715-21. PubMed ID: 23666093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiangiogenic and radiation therapy: early effects on in vivo computed tomography perfusion parameters in human colon cancer xenografts in mice.
    Ren Y; Fleischmann D; Foygel K; Molvin L; Lutz AM; Koong AC; Jeffrey RB; Tian L; Willmann JK
    Invest Radiol; 2012 Jan; 47(1):25-32. PubMed ID: 22178893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCE-MRI biomarkers for monitoring an anti-angiogenic triple combination therapy in experimental hypopharynx carcinoma xenografts with immunohistochemical validation.
    Sterzik A; Paprottka PM; Zengel P; Hirner H; Roßpunt S; Eschbach R; Moser M; Havla L; Ingrisch M; Mack B; Reiser MF; Nikolaou K; Cyran CC
    Acta Radiol; 2015 Mar; 56(3):294-303. PubMed ID: 24609871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.
    Tai JH; Tessier J; Ryan AJ; Hoffman L; Chen X; Lee TY
    Neoplasia; 2010 Sep; 12(9):697-707. PubMed ID: 20824046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
    Wilhelm SM; Dumas J; Adnane L; Lynch M; Carter CA; Schütz G; Thierauch KH; Zopf D
    Int J Cancer; 2011 Jul; 129(1):245-55. PubMed ID: 21170960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of the multikinase inhibitor regorafenib in patient-derived xenograft models of gastric cancer.
    Huynh H; Ong R; Zopf D
    J Exp Clin Cancer Res; 2015 Oct; 34():132. PubMed ID: 26514182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regorafenib suppresses colon tumorigenesis and the generation of drug resistant cancer stem-like cells via modulation of miR-34a associated signaling.
    Cai MH; Xu XG; Yan SL; Sun Z; Ying Y; Wang BK; Tu YX
    J Exp Clin Cancer Res; 2018 Jul; 37(1):151. PubMed ID: 30005681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
    Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
    Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
    Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.